Stocks Health care CLDI

NYSE · Health care

Calidi Biotherapeutics, Inc. (CLDI)

It posted a net loss of $17.5M. At June 30, 2026 it held $4.3M in cash against $600K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch CLDI in 60 seconds

What Calidi Biotherapeutics, Inc. does

Calidi Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker CLDI.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Calidi Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 25, 2026
   Stock exchange listing notice 8-K
2. September 22, 2026
   Material agreement 8-K
3. September 17, 2026
   Securities offering prospectus 424B5
4. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
5. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$2.94 versus -$31.75.
6. August 13, 2026
   Quarterly results 8-K
7. July 31, 2026
   Shareholder rights changed 8-K
8. July 16, 2026
   Material agreement 8-K
9. June 23, 2026
   Executive or director change 8-K
10. June 18, 2026
    Shareholder vote results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 19, 2026. Insider transactions on SEC

Insider trades

What the people running Calidi Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns CLDI

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Latest filings below 5%: Armistice Capital, LLC 4.99% (August 14, 2026); Gavrilov Ognian Anguelov 0.3% (March 31, 2026); Lincoln Alternative Strategies LLC 0% (February 10, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 76,952 shares in total, about $82.3K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CLDI

What does Calidi Biotherapeutics, Inc. do?

Calidi Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker CLDI.

Is Calidi Biotherapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $17.5M.

When did Calidi Biotherapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from September 25, 2026.

Similar companies

Compare CLDI with

Compare CLDI with any company

Follow CLDI

Get an email when Calidi Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CLDI: get an email when it files

Where the numbers come from

Financial figures are the values Calidi Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.